Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes

Itoh, Hiroyuki; Ando, Sugihiro; Tsugami, Emiko; Araki, Rie; Kusano, Eiji; Matsumoto, Suzuko; Uemura, Kosuke; Nishio, Shinya; Antoku, Shinichi; Yamasaki, Tomoko; Mori, Taisuke; Togane, Michiko

doi:10.1016/j.diabres.2019.05.025

Cited by 16 publications

(16 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there are also conflicting results. In a prospective study, adherence was improved by 0.1 point (p = 0.03) on the Diabetes Treatment Satisfactions Questionnaire (DTSQ) scale after patients switched from QD DPP4 inhibitors (i.e., sitagliptin, vildagliptin, alogliptin, linagliptin, and teneligliptin) to QW trelagliptin [ 60 ].…”

Section: Dipeptidyl Peptidase-4 Inhibitorsmentioning

confidence: 99%

Adherence and persistence rates of major antidiabetic medications: a review

Lee

2022

Diabetol Metab Syndr

View full text Add to dashboard Cite

The objective of this paper was to review the adherence and persistence rates of major antidiabetic medication classes (i.e., metformin, sulfonylureas, sodium glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, insulin, glucagon-like peptide-1 receptor agonists, and thiazolidinediones) by summarizing the major findings of the studies published since 2017. In addition, we reported the potential causes for low adherence and persistence of antidiabetic medications. Based on the literature, the highest rate of adherence and persistence was consistently observed in metformin users. Second to metformin were sodium glucose cotransporter-2 inhibitors. Injectable therapies such as insulin and glucagon-like peptide-1 receptor agonists trailed low on the adherence and persistence rates. To the best of our knowledge, no studies published since the year 2017 analyzed the adherence and persistence of thiazolidinediones independently. The most frequently cited cause for low adherence and persistence was the severity of adverse events. Baseline characteristics (e.g., baseline HbA1c level), demographic information (e.g., age, gender, or ethnicity), and comorbidity profiles also had significant impacts on adherence and persistence in patients with type 2 diabetes mellitus.

show abstract

Section: Dipeptidyl Peptidase-4 Inhibitorsmentioning

confidence: 99%

Adherence and persistence rates of major antidiabetic medications: a review

Lee

2022

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

“…When SGLT2 inhibitors were introduced to Japan, where elderly patients with type 2 diabetes account for much of the population [10,11], there were concerns about drug-related adverse events (AEs), such as fluid depletion and cerebral infarction. Therefore, the prescription rate of SGLT2 inhibitors had not been high [12], with dipeptidyl peptidase-4 (DPP-4) inhibitors most commonly used in real-world clinical practice for the treatment of Japanese patients with type 2 diabetes [13,14] because of their safety and reliability in glycemic control among elderly patients and subjects with renal impairment [15,16]. However, there has been no clear evidence to support the inhibition of cardiovascular events or diabetic nephropathy by DPP-4 inhibitors [17][18][19][20], although the glucose-lowering efficacy of DPP-4 inhibitors in patients with type 2 diabetes is better in Asians than in other ethnic groups [21].…”

Section: Introductionmentioning

confidence: 99%

Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aims The safety and efficacy, particularly, the factors associated with the renal prognosis, were assessed over 12 months after the initiation of luseogliflozin therapy in Japanese patients with type 2 diabetes and renal impairment. Methods In total, 238 patients treated with luseogliflozin (2.5 mg, once daily) were studied as the safety analysis set. Two hundred and two subjects whose medication was continued over 12 months were investigated as the full analysis set. The subjects were divided into 3 groups based on the estimated glomerular filtration rate (eGFR): high eGFR (n = 49), normal eGFR (n = 116) and low eGFR (n = 37) groups. Results The body weight, systolic blood pressure, HbA1c and urinary protein excretion gradually decreased from baseline in all eGFR groups. While the eGFR was significantly reduced from baseline in the high and normal eGFR groups, the eGFR did not significantly differ over time in the low eGFR group. There was no marked difference in the frequency of adverse events that were specific for SGLT2 inhibitors among the 3 groups in the safety analysis set. Conclusions Luseogliflozin can preserve the renal function in the medium term in patients with type 2 diabetes and renal impairment without an increase in specific adverse events.

show abstract

“…The aging of patients is closely related to frequent renal impairment in individuals with type 2 diabetic13,14 and such patients are considered to be at high risk for cardiovascular events 15,16. Thus, dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used in real-world clinical practice for the treatment of Japanese patients with type 2 diabetes9,10 because of safety and reliability from the viewpoint of AEs and glycemic control in elderly patients with renal impairment 17,18. However, there is no clear evidence to support the inhibition of cardiovascular events or diabetic nephropathy by DPP-4 inhibitors,19–22 although the glucose-lowering efficacy of DPP-4 inhibitors in Asians is better than that in other ethnic groups 23…”

Section: Introductionmentioning

confidence: 99%

<p>Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes</p>

Itoh¹,

Matsumoto²,

Izutsu³

et al. 2019

DMSO

Self Cite

View full text Add to dashboard Cite

PurposeThe factors associated with the renal prognosis over six months after the initiation of empagliflozin were compared between the non-elderly and elderly Japanese patients with type 2 diabetes.Patients and methodsIn total, 132 patients treated with empagliflozin (10 mg, once daily) were studied as the safety analysis set. One hundred ten subjects whose medications were not changed during the observation period were investigated as the full analysis set to assess the effectiveness. The subjects were divided into two groups: non-elderly subjects (n=72) of<65 years of age and elderly subjects (n=38) of≥65 years of age.ResultsAlthough the body weight and HbA1c, AST, ALT and γ-GTP levels were significantly reduced in both the non-elderly and elderly subjects, blood pressure, eGFR and urinary protein excretion were only significantly decreased in the non-elderly subjects. The hemoglobin, hematocrit and serum HDL-cholesterol levels were significantly elevated in both groups. The change in eGFR showed a significant positive association with the change in blood pressure. The change in urinary protein excretion tended to be correlated with the change in blood pressure.ConclusionAlthough renoprotective effects might be limited, empagliflozin can safely and effectively improve metabolic parameters, even in elderly subjects.

show abstract

Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes

Cited by 16 publications

References 28 publications

Adherence and persistence rates of major antidiabetic medications: a review

Adherence and persistence rates of major antidiabetic medications: a review

Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation

<p>Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes</p>

Contact Info

Product

Resources

About